Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.83 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252030 | 1.00 | DGAT1 (0.83) | DGAT1GSK3BKDRPDCD1CD274 | |
| SCHEMBL1252922 | 0.94 | DGAT1 (0.72) | DGAT1GSK3BKDRPDCD1CD274 | |
| SCHEMBL13695119 | 0.92 | DGAT1 (0.69) | DGAT1GSK3BKDR | |
| SCHEMBL30385298 | 0.91 | DGAT1 (1.00) | DGAT1CHEK2 | |
| SCHEMBL1252216 | 0.91 | DGAT1 (1.00) | DGAT1CHEK2 | |
| SCHEMBL1252747 | 0.85 | DGAT1 (0.85) | DGAT1KDRCHEK2 | |
| SCHEMBL1252829 | 0.85 | DGAT1 (0.64) | DGAT1PDCD1CD274 | |
| SCHEMBL10299677 | 0.82 | DGAT1 (0.83) | DGAT1CHEK2 | |
| SCHEMBL1252149 | 0.81 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL1250496 | 0.81 | DGAT1 (0.80) | DGAT1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |